MAM
Housejoy breaks the stereotype through their campaign ‘ShesTheFan’
BENGALURU: Cricket in India is a religion and Indians follow it devotedly. Men are as much of its followers and women are but on Indian television and commercials we see only men, of all ages and background, cheer on their favourite team. Why do we follow such clichés? Why are women not shown cheering with as much gusto and enthusiasm? Enter Housejoy’s latest video which intends to break the stereotype.
As the cricket frenzy catches the nation by storm Housejoy, the leader in home services category in India, releases a video on cricket that show both men and women watching cricket. The difference is that they show women enjoying cricket in their own style! In the ad, women are seen enjoying beauty services at their home while watching cricket.
So, this IPL season, sit back, relax and let Housejoy pamper you. Because #ShesTheFan.
The film has been directed by Saad Khan, founder and creative head of Centerstage. He is Bollywood and Hollywood Director.
Nikhil Kumar, Head of Marketing-Housejoy says, “Being the leader in beauty services at home, we have received many requests this season. Women love to order our beauty services and get pampered at home while watching cricket with friends/family. Strangely this insight has never been showcased on any cricket ad or spots who mainly reflect it as a game only viewed or enjoyed by men of all ages across the country. Since IPL is the flavour of the season, we decided to feature this unique consumer insight in this video.”
Talking about the film, Saad Khan Creative Director at Centrestage says, “Women enjoying cricket hasn’t been depicted before and with this film we really wanted to celebrate women. We have tried to bring an emotional aspect to the film and show the love of cricket from the nation. It was great to work with these lovely bunch of ladies who really know how to have fun.”
Here is the video – https://www.youtube.com/watch?v=0W1xJ0hcx3E&feature=youtu.be
Credits
Creative Agency: Centrestage
Director: Saad Khan
Script Writer: Ajay Bhaskar
Script Supervisor: Centerstage
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
